Mirchev MB, Boeva I, Peshevska-Sekulovska M, Stoitsov V, Peruhova M. Synchronous manifestation of colorectal cancer and intraductal papillary mucinous neoplasms. World J Clin Cases 2023; 11(15): 3408-3417 [PMID: 37383909 DOI: 10.12998/wjcc.v11.i15.3408]
Corresponding Author of This Article
Milena Peruhova, MD, Assistant Professor, Department of Gastroenterology, Heart and Brain Hospital, Zdrave 1 st, Burgas 8000, Bulgaria. mperuhova@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Milko Bozhidarov Mirchev, Irina Boeva, Veselin Stoitsov, Milena Peruhova, Department of Gastroenterology, Heart and Brain Hospital, Burgas 8000, Bulgaria
Monika Peshevska-Sekulovska, Department of Gastroenterology, University Hospital Lozenetz, Sofia 1407, Bulgaria
Author contributions: Mirchev M and Peruhova M wrote the majority of the manuscript; Boeva I and Peshevska-Sekulovska M prepared the figures and tables; Stoitsov V provided critical revision, designed the outline of the manuscript, and coordinated the writing of the paper.
Conflict-of-interest statement: All the authors report having no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Milena Peruhova, MD, Assistant Professor, Department of Gastroenterology, Heart and Brain Hospital, Zdrave 1 st, Burgas 8000, Bulgaria. mperuhova@gmail.com
Received: January 10, 2023 Peer-review started: January 10, 2023 First decision: February 8, 2023 Revised: February 26, 2023 Accepted: April 17, 2023 Article in press: April 17, 2023 Published online: May 26, 2023 Processing time: 134 Days and 19.4 Hours
Abstract
High rates of extrapancreatic malignancies, in particular colorectal cancer (CRC), have been detected in patients with intraductal papillary mucinous neoplasm (IPMN). So far, there is no distinct explanation in the literature for the development of secondary or synchronous malignancies in patients with IPMN. In the past few years, some data related to common genetic alterations in IPMN and other affiliated cancers have been published. This review elucidated the association between IPMN and CRC, shedding light on the most relevant genetic alterations that may explain the possible relationship between these entities. In keeping with our findings, we suggested that once the diagnosis of IPMN is made, special consideration of CRC should be undertaken. Presently, there are no specific guidelines regarding colorectal screening programs for patients with IPMN. We recommend that patients with IPMNs are at high-risk for CRC, and a more rigorous colorectal surveillance program should be implemented.
Core Tip: In this mini-review, we highlighted the genetic alterations that occur in intraductal papillary mucinous neoplasm (IPMN) and colorectal cancer to understand common genetic or epigenetic risk factors that could explain their synchronous manifestation. The process of malignant transformation in both entities is complex, but some distinctive features of IPMN lesions are linked with their genetic heterogeneity. Specific mutations in GNAS and KRAS are mainly expressed in IPMN. A significantly lower frequency of mutations is detected in other cancer-related genes, such as SMAD4, PI3KCA, PTEN, and BRAF.
